Ainos (STU:FZX0) Future Policy Benefits

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:FZX0 Ainos Inc STU:FZX0
20 GF Score
Price €12.50
GF Value €0.95
! 9 Warning Signs
View Full Analysis

What is Ainos Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.

STU:FZX0
20GF Score
Ainos Inc STU:FZX0
Future Policy Benefits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ainos (STU:FZX0) Overvalued in 2026?

Based on GuruFocus' analysis, Ainos stock appears to be overvalued. The current stock price of €12.50 is trading 1215.8% above its estimated GF Value™ of €0.95.

Key valuation signals for STU:FZX0:

  • Future Policy Benefits:
  • GF Value™: €0.95 vs. price of €12.50 (1215.8% above fair value)
  • GF Score™: 20/100 with 9 warning signs

No single metric tells the full story. See the STU:FZX0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ainos Business Description

Other Exchanges AIMD:USA
Address 3050 Post Oak Boulevard, Suite 510-T80, Houston, TX, USA, 77056
Ainos Inc is a technology company focused on artificial intelligence-driven scent digitization and immune therapeutics. Its primary platform, AI Nose, is an electronic olfaction system that combines gas sensor arrays with proprietary AI models, referred to as a smell language model, to convert scent and volatile organic compound signals into a machine-readable format called Smell ID. The company targets applications in healthcare, industrial monitoring, and consumer markets. Ainos also develops therapeutic assets through its low-dose oral interferon program, VELDONA, aimed at immune-related conditions. The company is based in the United States and pursues commercialization of its scent technology alongside its therapeutic development efforts. Its revenue model centers on licensing and deploying its AI Nose platform and advancing its drug candidates through clinical development.
20GF Score

Get the complete analysis for STU:FZX0

Future Policy Benefits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.50
Price
€0.95
GF Value